Anaplastic thyroid cancer

Last updated
Anaplastic thyroid cancer
Other namesAnaplastic thyroid carcinoma, ATC
Anaplastic thyroid carcinoma low mag.jpg
Microscopic image of anaplastic thyroid carcinoma. H&E stain.
Specialty ENT surgery, oncology, endocrinology
PreventionUse a thyroid guard when having any time of radiation, like X-rays or certain scans - even dental X-rays.
Treatment Chemotherapy, radiation therapy

Anaplastic thyroid cancer (ATC), also known as anaplastic thyroid carcinoma, is an aggressive form of thyroid cancer characterized by uncontrolled growth of cells in the thyroid gland. This form of cancer generally carries a very poor prognosis due to its aggressive behavior and resistance to cancer treatments. [1] The cells of anaplastic thyroid cancer are highly abnormal and usually no longer resemble the original thyroid cells and have poor differentiation.

Contents

ATC is an uncommon form of thyroid cancer only accounting for 1-2% of cases, but due to its high mortality, is responsible for 20-50% of deaths from thyroid cancer. [2] The median survival time after diagnosis is three to six months. [2] Some studies report that 10% to 15% survive more than 1 year; 3-year and 5-year survival is very rare. [3] [4] It occurs more commonly in women than in men and is seen most commonly in people ages 40 to 70. [2]

Signs and symptoms

Anaplastic thyroid cancer typically manifests as a rapidly enlarging neck mass. [2] Associated redness and swelling of the overlying skin sometimes occur. ATC commonly causes symptoms by compressing local structures, such as the esophagus, carotid arteries, recurrent laryngeal nerve, and trachea. This compression of local anatomic structures may cause symptoms such as difficulty controlling the voice, hoarseness, difficulty swallowing, or trouble breathing. [2] Other symptoms include cough, neck pain, or symptoms from the spread of cancer to distant sites in the body, such as the brain. ATC may rarely present with coughing up blood. [2]

Causes

Risk factors include being over the age of sixty, a long-standing goiter, and repeated radiation exposure to the chest or neck.

Pathogenesis

Nearly half of ATC cases occur in the setting of coexisting differentiated thyroid cancer. This suggests that many ATC cases have dedifferentiated from differentiated thyroid cancer and, as a result, become more aggressive and difficult to treat. Differentiated thyroid cancer is seen coexisting with ATC on fine-needle aspiration biopsies in 20-50% of cases. [2]

Anaplastic tumors have a high mitotic rate and frequently invades the local blood and lymphatic vessels. [5] Cellular death is frequently visualized on microscopic images. [2] The presence of regionally swollen lymph nodes in older patients in whom needle aspiration biopsy reveals characteristic vesicular appearance of the nuclei supports a diagnosis of anaplastic carcinoma. Microscopic images of ATC usually show inflammatory cells from the immune system such as T cells and macrophages. [2]

On immunohistochemistry testing, ATC is usually positive for the keratin, p53, and PAX8 proteins and is negative for thyroid transcription factor-1, thyroglobulin, and calcitonin. [2] ATC cells demonstrate high levels of PD-L1 expression. [2] BRAF and TERT mutations are seen more commonly in ATC than in differentiated thyroid cancer. [2]

Diagnosis

Fine-needle aspiration is essential in order to obtain a sample of the thyroid tissue to allow for microscopic examination. This allows an experienced pathologist to differentiate ATC from other diseases, such as other forms of thyroid cancer. [2] It is very important to distinguish between ATC and poorly-differentiated thyroid cancer and this distinction can be difficult to make. [2] The presence of PAX-8 positive staining and association with a different thyroid cancer that is adjacent to the ATC support the diagnosis. [2]

ATC is divided into several different subclasses based on its microscopic characteristics. These include sarcomatoid, squamoid, osteoclastic, paucicellular, rhabdoid, and carcinomasarcoid variants. [2] As of 2019, despite the fact that these ATC subtypes are recognized, this classification has not led to differences in management. [2] ATC is always considered to be stage IV when it is diagnosed. [6]

There are no reliable laboratory tests for ATC. [2] Ultrasound imaging of ATC lesions reveals a hypoechoic mass (appears dark on ultrasound) with invasion of the local structures and may help to better characterize the presence or absence of neck lymph node metastases. [2] If surgery is planned, however, then a contrast-enhanced computed tomography (CT) scan of the neck must be performed. [2] A PET scan is preferred for staging ATC but a CT scan of the neck, chest, abdomen, and pelvis can be substituted if the former is unavailable. [2] Magnetic resonance imaging (MRI) of the brain is also recommended to assess for distant metastases. [2]

Differential diagnosis

In addition to ATC, a rapidly enlarging neck mass prompts consideration of several other important diagnoses. These include other cancers such as primary thyroid lymphoma, poorly differentiated thyroid cancer, sarcomas, and metastases from cancers of the upper digestive tract and respiratory tract. [2] Squamous cell carcinoma of the thyroid gland is a rare cause of this presentation. [2]

Prevention

Management

Anaplastic thyroid cancer seen on an ultrasound image Anaplastic thyroid cancer 0001.jpg
Anaplastic thyroid cancer seen on an ultrasound image
Anaplastic thyroid carcinoma cells Anaplastic thyroid carcinoma cell No.2.jpg
Anaplastic thyroid carcinoma cells

ATC is considered an emergency cancer diagnosis since it poses a high risk of blocking the airway and/or esophagus due to its rapid growth in the neck, either of which can quickly cause a person's death by asphyxiation, if not immediately corrected. [2]

Unlike its differentiated counterparts, anaplastic thyroid cancer is highly unlikely to be curable either by surgery or by any other treatment modality, and is in fact usually unresectable due to its high propensity for invading surrounding tissues. [7] A multidisciplinary team including an endocrine pathologist, head and neck surgeon, medical oncologist, radiation oncologist, endocrinologist, and a palliative care physician is essential for optimal management. [2] Palliative treatment consists of radiation therapy usually combined with chemotherapy.

The use of tracheostomy as part of supportive care for ATC is controversial. [2]

Medications, such as fosbretabulin (a type of combretastatin), bortezomib and TNF-Related Apoptosis Induced Ligand (TRAIL), are, however, under investigation in vitro and in human clinical studies. Based on encouraging Phase I and II clinical trial results with fosbretabulin, [8] a type of medication that selectively destroys tumor blood vessels, clinical trials have been evaluating whether the medication can extend the survival of patients with ATC. [9]

With the advent of molecular testing and next-generation sequencing, BRAF and MEK inhibitors are playing an increasing role in the management of patients with anaplastic thyroid cancer harboring such mutations. The combination of dabrafenib and trametinib has shown significant increases in overall survival and has been approved by the FDA. Another similar combination is vemurafenib and cobimetinib.

Immunotherapy is also starting to play an important role in anaplastic thyroid cancer management with several ongoing clinical trials demonstrating promising effects. Specific drugs being tested are atezolizumab, pembrolizumab, and spartalizumab, amongst others.

Combinatorial therapy that is molecular-based may lead to significant tumor regression, potentially making patients amenable to curative surgery. [10]

Post-operative radiotherapy

The role of external beam radiotherapy (EBRT) in thyroid cancer remains controversial and there is no level I evidence to recommend its use in the setting of differentiated thyroid cancers such as papillary and follicular carcinomas. Anaplastic thyroid carcinomas, however, are histologically distinct from differentiated thyroid cancers and due to the highly aggressive nature of ATC aggressive postoperative radiation and chemotherapy are typically recommended.

The National Comprehensive Cancer Network Clinical Practice Guidelines currently recommend that postoperative radiation and chemotherapy be strongly considered. No published randomized controlled trials have examined the addition of EBRT to standard treatment, namely surgery. Radioactive iodine is typically ineffective in the management of ATC as it is not an iodine-avid cancer. [11]

Imbalances in age, sex, completeness of surgical excision, histological type and stage, between patients receiving and not receiving EBRT, confound retrospective studies. Variability also exists between treatment and non-treatment groups in the use of radio-iodine and post-treatment thyroid stimulating hormone (TSH) suppression and treatment techniques between and within retrospective studies.

Some recent studies have indicated that EBRT may be promising, though the number of patients studies has been small. [12]

Clinical trials for investigational treatments are often considered by healthcare professionals and patients as first-line treatment.

Add-on therapy

In the absence of extracervical or unresectable disease, surgical excision should be followed by adjuvant radiotherapy. In the 18–24% of patients whose tumour seems both confined to the neck and grossly resectable, complete surgical resection followed by adjuvant radiotherapy and chemotherapy could yield a 75–80% survival at 2 years.

There are a number of clinical trials for anaplastic thyroid carcinoma underway or being planned. [13]

Prognosis

The overall 5-year survival rate of anaplastic thyroid cancer has been given as 7% [14] or 14%, [15] although the latter has been criticized as being overestimated. [15] Additional factors that affect prognosis include the person's age, the presence of distant metastases, the dose of radiation administered to the primary tumor and regional lymph nodes, and if combined modality treatment is used. [2]

Treatment of anaplastic thyroid cancer is generally palliative in its intent due to its highly aggressive nature and nearly universal mortality. Larger tumors, distant metastases, acute obstructive symptoms, and leukocytosis portend a poorer prognosis. Death is attributable to upper airway obstruction and suffocation in half of patients, and to a combination of complications of local and distant disease, or therapy, or both in the remainder.

Anaplastic thyroid cancer is extremely aggressive; historically, in most cases death occurs in less than 1 year as a result of aggressive local growth and compromise of vital structures in the neck. ATC in most series has a median survival of 4 to 5 months from the time of diagnosis, with rare long-term survivors. [16]

Recent data however suggests that patients with BRAFV600E mutated disease, even if in an advanced stage, may have significantly better prognosis, as novel targeted therapies can extend tumor control considerably, while also leading to tumor burden decrease and potentially make patients candidates for surgery. [10] Recent advances show that using a combination of novel targeted therapies, immunotherapy, and surgery, 1 year and 2 year survival for anaplastic thyroid cancer patients have increased to 59% and 42%, respectively. [10]

Epidemiology

History

Research directions

Notable cases

Related Research Articles

<span class="mw-page-title-main">Brain tumor</span> Neoplasm in the brain

A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors: malignant tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

<span class="mw-page-title-main">Sarcoma</span> Medical condition

A sarcoma is a malignant tumor, a type of cancer that arises from cells of mesenchymal origin. Connective tissue is a broad term that includes bone, cartilage, fat, vascular, or other structural tissues, and sarcomas can arise in any of these types of tissues. As a result, there are many subtypes of sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates. Sarcomas are primary connective tissue tumors, meaning that they arise in connective tissues. This is in contrast to secondary connective tissue tumors, which occur when a cancer from elsewhere in the body spreads to the connective tissue. Sarcomas are one of five different types of cancer, classified by the cell type from which they originate. The word sarcoma is derived from the Greek σάρκωμα sarkōma 'fleshy excrescence or substance', itself from σάρξsarx meaning 'flesh'.

<span class="mw-page-title-main">Bone tumor</span> Medical condition

A bone tumor is an abnormal growth of tissue in bone, traditionally classified as noncancerous (benign) or cancerous (malignant). Cancerous bone tumors usually originate from a cancer in another part of the body such as from lung, breast, thyroid, kidney and prostate. There may be a lump, pain, or neurological signs from pressure. A bone tumor might present with a pathologic fracture. Other symptoms may include fatigue, fever, weight loss, anemia and nausea. Sometimes there are no symptoms and the tumour is found when investigating another problem.

<span class="mw-page-title-main">Endometrial cancer</span> Uterine cancer that is located in tissues lining the uterus

Endometrial cancer is a cancer that arises from the endometrium. It is the result of the abnormal growth of cells that have the ability to invade or spread to other parts of the body. The first sign is most often vaginal bleeding not associated with a menstrual period. Other symptoms include pain with urination, pain during sexual intercourse, or pelvic pain. Endometrial cancer occurs most commonly after menopause.

<span class="mw-page-title-main">Ovarian cancer</span> Cancer originating in or on the ovary

Ovarian cancer is a cancerous tumor of an ovary. It may originate from the ovary itself or more commonly from communicating nearby structures such as fallopian tubes or the inner lining of the abdomen. The ovary is made up of three different cell types including epithelial cells, germ cells, and stromal cells. When these cells become abnormal, they have the ability to divide and form tumors. These cells can also invade or spread to other parts of the body. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. These symptoms may include bloating, vaginal bleeding, pelvic pain, abdominal swelling, constipation, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver.

<span class="mw-page-title-main">Head and neck cancer</span> Cancer arises in the head or neck region

Head and neck cancer develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary glands, nose, sinuses, or skin of the face. The most common types of head and neck cancer occur in the lips, mouth, and larynx. Symptoms predominantly include a sore that does not heal or a change in the voice. In those with advanced disease, there may be unusual bleeding, facial pain, numbness or swelling, and visible lumps on the outside of the neck or oral cavity. Given the location of these cancers, it is possible for an afflicted individual to experience difficulty in breathing.

<span class="mw-page-title-main">Small-cell carcinoma</span> Type of malignant cancer

Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal tract. Compared to non-small cell carcinoma, small cell carcinoma is more aggressive, with a shorter doubling time, higher growth fraction, and earlier development of metastases.

<span class="mw-page-title-main">Glioblastoma</span> Aggressive type of brain cancer

Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has very poor prognosis for survival. Initial signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Symptoms often worsen rapidly and may progress to unconsciousness.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

<span class="mw-page-title-main">Hemangiopericytoma</span> Medical condition

A hemangiopericytoma is a type of soft-tissue sarcoma that originates in the pericytes in the walls of capillaries. When inside the nervous system, although not strictly a meningioma tumor, it is a meningeal tumor with a special aggressive behavior. It was first characterized in 1942.

<span class="mw-page-title-main">Papillary thyroid cancer</span> Medical condition

Papillary thyroid cancer is the most common type of thyroid cancer, representing 75 percent to 85 percent of all thyroid cancer cases. It occurs more frequently in women and presents in the 20–55 year age group. It is also the predominant cancer type in children with thyroid cancer, and in patients with thyroid cancer who have had previous radiation to the head and neck. It is often well-differentiated, slow-growing, and localized, although it can metastasize.

<span class="mw-page-title-main">Signet ring cell carcinoma</span> Medical condition

Signet ring cell carcinoma (SRCC) is a rare form of highly malignant adenocarcinoma that produces mucin. It is an epithelial malignancy characterized by the histologic appearance of signet ring cells.

Cancer of unknown primary origin (CUP) is a cancer that is determined to be at the metastatic stage at the time of diagnosis, but a primary tumor cannot be identified. A diagnosis of CUP requires a clinical picture consistent with metastatic disease and one or more biopsy results inconsistent with a tumor cancer

<span class="mw-page-title-main">Follicular thyroid cancer</span> Medical condition

Follicular thyroid cancer accounts for 15% of thyroid cancer and occurs more commonly in women over 50 years of age. Thyroglobulin (Tg) can be used as a tumor marker for well-differentiated follicular thyroid cancer. Thyroid follicular cells are the thyroid cells responsible for the production and secretion of thyroid hormones.

<span class="mw-page-title-main">Medullary thyroid cancer</span> Malignant thyroid neoplasm originating from C-cells

Medullary thyroid cancer is a form of thyroid carcinoma which originates from the parafollicular cells, which produce the hormone calcitonin. Medullary tumors are the third most common of all thyroid cancers and together make up about 3% of all thyroid cancer cases. MTC was first characterized in 1959.

<span class="mw-page-title-main">Esthesioneuroblastoma</span> Medical condition

Esthesioneuroblastoma is a rare cancer of the nasal cavity. Arising from the upper nasal tract, esthesioneuroblastoma is believed to originate from sensory neuroepithelial cells, also known as neuroectodermal olfactory cells.

<span class="mw-page-title-main">Thyroid cancer</span> Medical condition

Thyroid cancer is cancer that develops from the tissues of the thyroid gland. It is a disease in which cells grow abnormally and have the potential to spread to other parts of the body. Symptoms can include swelling or a lump in the neck. Cancer can also occur in the thyroid after spread from other locations, in which case it is not classified as thyroid cancer.

<span class="mw-page-title-main">Brain metastasis</span> Cancer that has metastasized (spread) to the brain from another location in the body

A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, as primary tumors that originate in the brain are less common. The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain metastases can occur in patients months or even years after their original cancer is treated. Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years after the diagnosis.

Carcinoma of the tonsil is a type of squamous cell carcinoma. The tonsil is the most common site of squamous cell carcinoma in the oropharynx. It comprises 23.1% of all malignancies of the oropharynx. The tumors frequently present at advanced stages, and around 70% of patients present with metastasis to the cervical lymph nodes. . The most reported complaints include sore throat, otalgia or dysphagia. Some patients may complain of feeling the presence of a lump in the throat. Approximately 20% patients present with a node in the neck as the only symptom.

<span class="mw-page-title-main">Ovarian squamous cell carcinoma</span> Medical condition

Ovarian squamous cell carcinoma (oSCC) or squamous ovarian carcinoma (SOC) is a rare tumor that accounts for 1% of ovarian cancers. Included in the World Health Organization's classification of ovarian cancer, it mainly affects women above 45 years of age. Survival depends on how advanced the disease is and how different or similar the individual cancer cells are.

References

  1. ↑ Liu AH, Juan LY, Yang AH, Chen HS, Lin HD (2006). "Anaplastic thyroid cancer with uncommon long-term survival". J Chin Med Assoc. 69 (10): 489–91. doi:10.1016/S1726-4901(09)70314-4. PMID   17098674.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Chintakuntlawar, AV; Foote, RL; Kasperbauer, JL; Bible, KC (March 2019). "Diagnosis and Management of Anaplastic Thyroid Cancer". Endocrinology and Metabolism Centers of North America (Review). 48 (1): 269–84. doi:10.1016/j.ecl.2018.10.010. PMID   30717908. S2CID   73415858.
  3. ↑ Zivaljevic, Vladan, MD, PhD, Vlajinac, Hristina, et al. Case-Control Study of Anaplastic Thyroid Cancer: Papillary Thyroid Cancer Patients as Controls. Endocrinologist. 2010;20(6):308-311. doi:10.1097/TEN.0b013e3181fd02f2.
  4. ↑ Rodriguez JM, Pinero A, Ortiz S, et al. Clinical and histological differences in anaplastic thyroid carcinoma. Eur J Surg. 2000;166:34-38.
  5. ↑ Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont JP. "Thyroid and Parathyroid Cancers" Archived 2010-02-28 at the Wayback Machine in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach Archived 2013-10-04 at the Wayback Machine . 11 ed. 2008.
  6. ↑ Harrison's Principles of Internal Medicine, 18th edition, p.2934
  7. ↑ Haigh PI (2000). "Anaplastic thyroid carcinoma". Curr Treat Options Oncol. 1 (4): 353–7. doi:10.1007/s11864-000-0051-8. PMID   12057160. S2CID   2087282.
  8. ↑ Granata, Roberta; Locati, Laura D.; Licitra, Lisa (October 2014). "Fosbretabulin for the treatment of anaplastic thyroid cancer". Future Oncology (London, England). 10 (13): 2015–2021. doi:10.2217/fon.14.154. ISSN   1744-8301. PMID   25396774.
  9. ↑ Sosa, Julie A.; Elisei, Rossella; Jarzab, Barbara; Balkissoon, Jai; Lu, Shiao-ping; Bal, Chandrasekhar; Marur, Shanthi; Gramza, Ann; Yosef, Rami Ben; Gitlitz, Barbara; Haugen, Bryan R.; Ondrey, Frank; Lu, Charles; Karandikar, S.M.; Khuri, Fadlo; Licitra, Lisa; Remick, Scot C. (February 2014). "Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma". Thyroid. 24 (2): 232–240. doi:10.1089/thy.2013.0078. PMID   23721245.
  10. 1 2 3 Maniakas A, Dadu R, et al., Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019 "JAMA Oncology",https://jamanetwork.com/journals/jamaoncology/article-abstract/2769127
  11. ↑ Ford D, Giridharan S, McConkey C, et al. (2003). "External beam radiotherapy in the management of differentiated thyroid cancer". Clin Oncol (R Coll Radiol). 15 (6): 337–41. doi:10.1016/S0936-6555(03)00162-6. PMID   14524487.
  12. ↑ Meadows KM, Amdur RJ, Morris CG, Villaret DB, Mazzaferri EL, Mendenhall WM (2006). "External beam radiotherapy for differentiated thyroid cancer". Am J Otolaryngol. 27 (1): 24–8. doi:10.1016/j.amjoto.2005.05.017. PMID   16360819.
  13. ↑ "American Thyroid Association - Thyroid Clinical Trials". Archived from the original on 12 December 2007. Retrieved 2007-12-21.
  14. ↑ cancer.org > Thyroid Cancer Archived 2013-10-18 at the Wayback Machine By the American Cancer Society. In turn citing: AJCC Cancer Staging Manual (7th ed).
  15. 1 2 Numbers from National Cancer Database in the US, from Page 10 in: F. Grünwald; Biersack, H. J.; Grünwald, F. (2005). Thyroid cancer. Berlin: Springer. ISBN   978-3-540-22309-2. (Note:Book also states that the 14% 10-year survival for anaplastic thyroid cancer was overestimated)
  16. ↑ Kumar V, Abbas AK, Fausto N, and Mitchel RN, "Robbins basic Pathology", Saunders, 8th ed., 2007.
  17. ↑ Rajan, Greg (October 29, 2017). "Astros manager A.J. Hinch stands up for friend Kevin Towers". Houston Chronicle.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.